Dr. Andrew Wei, a leading expert in acute myeloid leukemia from the Peter McCallum Cancer Center, discusses the innovative use of venetoclax in treating AML. He highlights groundbreaking clinical trials that have transformed treatment pathways, particularly for older patients. Innovative therapies like venetoclax combined with hypomethylating agents are explored, along with ongoing resistance challenges and the role of genetic mutations in personalized treatment. The conversation also touches on the implications of minimal residual disease negativity in enhancing patient outcomes.

In a deep dive into myelodysplastic syndromes, Andrew Wei, an expert from Alfred Hospital and Monash University, discusses the dual roles of inflammation and immune interventions. He highlights the critical targeting of STAT and IRAK4, accompanied by insights from the STIMULUS-MDS2 trial on sabatolimab. The conversation also touches on the importance of learning from past clinical trial pitfalls, the potential of targeted therapies, and how overcoming challenges in drug development could revolutionize MDS treatment.

Andrew Wei, an expert in acute myeloid leukemia, discusses the relevance of TP53 mutation in AML. Topics include diagnostic approaches, defining double hit TP53, risk assessment, and potential treatments for P53 mutant AML.

Guests Thomas Cluzeau, Naval Daver, and Andrew Wei discuss the latest AML therapies, including the use of CPX351 as a potential cure for certain patients, the safety and efficacy of Magrola MAB in combination with azacitidine, the high response rates and safety profile of treatment for TP53 AML patients, and updates on Venetoclax plus low dose Cytarabine study in previously untreated older AML patients.

Marion Subklewe, Amir Fathi, and Andrew Wei discuss emerging immunotherapies, venetoclax-based regimens, and targeted therapies in AML. They explore challenges in translating successful treatment strategies, discuss treatment options and challenges for TP53 mutated AML patients, and highlight the importance of targeted therapies. The speakers also delve into designing frontline phase three studies for older AML patients and the challenges of label expansion for emerging immunotherapies.